Randomized phase II study of fulvestrant and erlotinib compared with erlotinib alone in patients with advanced or metastatic non-small cell lung cancer
- 1 September 2018
- journal article
- research article
- Published by Elsevier in Lung Cancer
- Vol. 123, 91-98
Abstract
No abstract availableKeywords
Funding Information
- AstraZeneca
- Genentech
This publication has 51 references indexed in Scilit:
- Maintenance erlotinib versus erlotinib at disease progression in patients with advanced non-small-cell lung cancer who have not progressed following platinum-based chemotherapy (IUNO study)Lung Cancer, 2016
- Analysis of estrogens and androgens in postmenopausal serum and plasma by liquid chromatography–mass spectrometrySteroids, 2015
- Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trialThe Lancet Oncology, 2013
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialThe Lancet Oncology, 2012
- Suppression of estrogen actions in human lung cancerMolecular and Cellular Endocrinology, 2011
- Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trialThe Lancet, 2009
- Pilot study of gefitinib and fulvestrant in the treatment of post-menopausal women with advanced non-small cell lung cancerLung Cancer, 2009
- Detection of epidermal growth factor receptor and human epidermal growth factor receptor 2 activating mutations in lung adenocarcinoma by high-resolution melting amplicon analysis: correlation with gene copy number, protein expression, and hormone receptor expressionHuman Pathology, 2006
- Estrogen and growth factor receptor interactions in human breast and non-small cell lung cancer cellsSteroids, 2005
- Molecular mechanism of estrogen receptor (ER)α-specific, estradiol-dependent expression of the progesterone receptor (PR) B-isoformThe Journal of Steroid Biochemistry and Molecular Biology, 2004